Source: International Congress 2019 – Complex respiratory infections in clinical practice
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Perez (Barcelona, Spain), E. Polverino (Barcelona, Spain), A. Alvares (Barcelona, Spain), P. Chang (Barcelona, Spain), L. Traversi (Varese, Italy), A. Rando (Barcelona, Spain), D. Romero (Barcelona, Spain), M. Martin (Barcelona, Spain). Prevalence of relevant multi-drug resistant (MDR) pathogens in a bronchiectasis (BE) cohort.. 4580

Member's Comments

No comment yet.

Related content which might interest you: Are multi-drug resistant (MDR) pathogens related to higher mortality in pneumonia? Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Drug resistance patterns in patients with multi-drug resistant tuberculosis (MDR – TB) Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012 Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR) Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003 Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB. Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 Recurrence after successful treatment of pulmonary tuberculosis (TB) with multidrug-resistance (MDR) Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Short course of chemotherapy of multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Change in the susceptibility pattern of Streptococcus pneumoniae (SP) and risk factors (RF) for antibiotic resistance (AR) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 546s Year: 2003 Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: epidemiology, diagnosis and treatment Source: Annual Congress 2008 - Infection year in review Year: 2008 Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Bio-Chip (BCh) technology for diagnostics of multidrug resistance (DR) of mycobacterium tuberculosis (MBT) from patients with disseminated tuberculosis (DT) Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008